Literature DB >> 11408338

The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK.

U Nath1, Y Ben-Shlomo, R G Thomson, H R Morris, N W Wood, A J Lees, D J Burn.   

Abstract

We performed a study to estimate the point prevalence of progressive supranuclear palsy (PSP) in the UK at national, regional and community levels. A 'Russian doll' design was used in which the population denominator for each of the three studies was successively smaller, whilst the method of case ascertainment became increasingly more rigorous. The NINDS-SPSP (National Institute of Neurological Disorders and the Society for Progressive Supranuclear Palsy) diagnostic criteria for PSP were applied throughout the study for case definition. The national study identified cases using passive referral mechanisms [e.g. the British Neurological Surveillance Unit (BNSU), PSP (Europe) Association patient register]. We identified 577 cases of PSP, giving a national prevalence estimate of 1.0 per 100 000 [95% confidence interval (CI) 0.9-1.1]. The North of England regional study used active 'multiple source' case ascertainment from a collaborative network of neurologists and non-neurologists. We identified 80 cases of PSP in this study, giving a crude and age-adjusted prevalence of 3.1 (95% CI 2.4-3.8) and 2.4 (1.9-3.0) per 100 000, respectively. Of these 80 cases, 51 patients (65%) were referred initially to non-neurologists and 10 patients (13%) had not seen a neurologist at any stage of their illness. The proportion of female cases was significantly greater in the regional than in the national study (61% versus 44%; P < 0.02). Cases referred to non-neurologists were significantly older than those referred to neurologists in the regional study (median age 73 versus 69.5 years; P < 0.01). Patients in the community study were identified via diagnostic and therapeutic registers from a representative sample of general practices in Newcastle upon Tyne. We identified 17 cases of PSP, yielding crude and age-adjusted prevalences of 6.5 (95% CI 3.4-9.7) and 5.0 (95% CI 2.5-7.5) per 100 000, respectively. Seven of the 17 cases (41%) had not previously been diagnosed as PSP. This study suggests that PSP is more common than previously considered, is commonly misdiagnosed and that the majority of cases are not initially referred to neurologists. The study also confirms the importance of active and detailed case ascertainment in ensuring reliable prevalence estimates.

Entities:  

Mesh:

Year:  2001        PMID: 11408338     DOI: 10.1093/brain/124.7.1438

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  56 in total

1.  Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP?

Authors:  Virgilio Gerald H Evidente; Charles H Adler; Marwan N Sabbagh; Donald J Connor; Joseph G Hentz; John N Caviness; Lucia I Sue; Thomas G Beach
Journal:  Parkinsonism Relat Disord       Date:  2011-03-21       Impact factor: 4.891

Review 2.  Other dementias.

Authors:  Gaida Krumina
Journal:  Neuroradiology       Date:  2011-09       Impact factor: 2.804

3.  Targeting the low-hanging fruit of neurodegeneration.

Authors:  Amanda R Mason; Adam Ziemann; Steven Finkbeiner
Journal:  Neurology       Date:  2014-10-14       Impact factor: 9.910

Review 4.  Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches.

Authors:  Nikolaus R McFarland; Christopher W Hess
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

5.  Familial aggregation in atypical Parkinson's disease: a case control study in multiple system atrophy and progressive supranuclear palsy.

Authors:  Jean-Sébastien Vidal; Marie Vidailhet; Pascal Derkinderen; Christophe Tzourio; Annick Alpérovitch
Journal:  J Neurol       Date:  2010-07-13       Impact factor: 4.849

6.  Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress.

Authors:  Shauna H Yuan; Nobuhiko Hiramatsu; Qing Liu; Xuehan Victoria Sun; David Lenh; Priscilla Chan; Karen Chiang; Edward H Koo; Aimee W Kao; Irene Litvan; Jonathan H Lin
Journal:  Hum Mol Genet       Date:  2018-11-15       Impact factor: 6.150

7.  Population based study of late onset cerebellar ataxia in south east Wales.

Authors:  M B Muzaimi; J Thomas; S Palmer-Smith; L Rosser; P S Harper; C M Wiles; D Ravine; N P Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

Review 8.  Essential tremor followed by progressive supranuclear palsy: postmortem reports of 11 patients.

Authors:  Elan D Louis; Rachel Babij; Karen Ma; Etty Cortés; Jean-Paul G Vonsattel
Journal:  J Neuropathol Exp Neurol       Date:  2013-01       Impact factor: 3.685

Review 9.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Authors:  Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2012-10-10       Impact factor: 21.566

10.  Progressive supranuclear palsy: high-field-strength MR microscopy in the human substantia nigra and globus pallidus.

Authors:  Parastou Foroutan; Melissa E Murray; Shinsuke Fujioka; Katherine J Schweitzer; Dennis W Dickson; Zbigniew K Wszolek; Samuel C Grant
Journal:  Radiology       Date:  2012-11-14       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.